160 related articles for article (PubMed ID: 35657923)
21. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
22. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.
Klaassen Z; Howard LE; de Hoedt A; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Cancer; 2017 May; 123(9):1528-1535. PubMed ID: 28026865
[TBL] [Abstract][Full Text] [Related]
23. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.
Brown JE; Cook RJ; Lipton A; Coleman RE
Clin Cancer Res; 2012 Nov; 18(22):6348-55. PubMed ID: 22952345
[TBL] [Abstract][Full Text] [Related]
24. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
[TBL] [Abstract][Full Text] [Related]
25. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
[TBL] [Abstract][Full Text] [Related]
26. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
Oster G; Lamerato L; Glass AG; Richert-Boe KE; Lopez A; Chung K; Richhariya A; Dodge T; Wolff GG; Balakumaran A; Edelsberg J
Support Care Cancer; 2013 Dec; 21(12):3279-86. PubMed ID: 23884473
[TBL] [Abstract][Full Text] [Related]
27. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
[TBL] [Abstract][Full Text] [Related]
28. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases.
Hagiwara M; Delea TE; Chung K
J Med Econ; 2014 Mar; 17(3):223-30. PubMed ID: 24494707
[TBL] [Abstract][Full Text] [Related]
29. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
Snedecor SJ; Carter JA; Kaura S; Botteman MF
Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
[TBL] [Abstract][Full Text] [Related]
32. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
Sun JM; Ahn JS; Lee S; Kim JA; Lee J; Park YH; Park HC; Ahn MJ; Ahn YC; Park K
Lung Cancer; 2011 Jan; 71(1):89-93. PubMed ID: 20598769
[TBL] [Abstract][Full Text] [Related]
33. Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma.
Jeon HL; Oh IS; Baek YH; Yang H; Park J; Hong S; Shin JY
J Bone Miner Metab; 2020 Mar; 38(2):254-263. PubMed ID: 31673791
[TBL] [Abstract][Full Text] [Related]
34. Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan.
Chiang PH; Wang HC; Lai YL; Chen SC; Yen-Hwa W; Kok CK; Ou YC; Huang JS; Huang TC; Chao TY
J Cancer Res Ther; 2013; 9(4):653-9. PubMed ID: 24518712
[TBL] [Abstract][Full Text] [Related]
35. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
[TBL] [Abstract][Full Text] [Related]
36. External beam radiation therapy (EBRT) for asymptomatic bone metastases in patients with solid tumors reduces the risk of skeletal-related events (SREs).
Shulman RM; Meyer JE; Li T; Howell KJ
Ann Palliat Med; 2019 Apr; 8(2):159-167. PubMed ID: 30525770
[TBL] [Abstract][Full Text] [Related]
37. Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).
Barnadas A; Manso L; de la Piedra C; Meseguer C; Crespo C; Gómez P; Calvo L; Martinez P; Ruiz-Borrego M; Perelló A; Antón A; Codes M; Margelí M; Murias A; Salvador J; Seguí MÁ; de Juan A; Gavilá J; Luque M; Pérez D; Zamora P; Arizcuma A; Chacón JI; Heras L; Martin-Fernández M; Mahillo-Fernández I; Tusquets I
Bone; 2014 Nov; 68():32-40. PubMed ID: 25108081
[TBL] [Abstract][Full Text] [Related]
38. Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma.
Orita Y; Sugitani I; Toda K; Manabe J; Fujimoto Y
Thyroid; 2011 Jan; 21(1):31-5. PubMed ID: 21058881
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M
Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]